Consolidating adverse event databases is a smart move, but without public education, real-time transparency risks becoming ...
Nearly a quarter of stays among an 11-hospital sample of roughly 2,800 admissions included at least one adverse event, and about 7% of admissions included an adverse event that could have been ...
Consolidation into AEMS removes fragmented querying across seven systems, improving accessibility of population-level safety signals relevant to pharmacovigilance and competitive intelligence.
Discovery of immune checkpoint inhibitors has revolutionized the therapeutic landscape for the treatment of cancer. Development of immunotherapy for cancer is based on modulation of T cell function ...
The US Food and Drug Administration (FDA) announced it is unifying its various adverse reporting systems into a single system called the Adverse Event Monitoring System (AEMS). The agency said the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results